ClinOps Optimizer
Causal-ML driven site selection and real-time trial performance analytics
Software · Cloud SaaSCompany source
Company profile
About PhaseV
PhaseV is a clinical trial optimization platform that leverages artificial intelligence and machine learning to transform how biopharma companies and contract research organizations (CROs) design and execute clinical trials. The company provides a comprehensive suite of AI-powered solutions that optimize every phase of the clinical trial process, from trial design and patient selection to site selection and real-time monitoring. PhaseV's platform includes four core products: Trial Optimizer for running millions of trial simulations to refine adaptive, Bayesian, and fixed designs; Response Optimizer for identifying optimal patient subgroups and biomarkers by detecting heterogeneity in clinical data; Portfolio Optimizer for uncovering biological factors driving disease progression using AI-driven causal graphs; and ClinOps Optimizer for precision-guided site selection and real-time trial performance analytics. The company serves over 40 biopharma companies and CROs globally, delivering proven outcomes including 40% reduced enrollment, 50% lower trial costs, 40% shorter trial duration, and 30%+ higher probability of success. PhaseV's approach combines causal machine learning with patient-level data from over 2 million patients across multiple therapeutic areas, enabling sponsors to make data-driven decisions backed by advanced analytics and predictive models. The platform has demonstrated success across multiple therapeutic areas including oncology, metabolic diseases, immunology, neurology, rheumatology, and infectious diseases, with validated case studies showing significant improvements in trial efficiency and patient outcomes.
Company description PhaseV official website
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at PhaseV?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- ALS (Neurology)
- Gastrointestinal Diseases
- Immunology
- Infectious Disease
- Kidney Disease
- Oncology (Solid Tumors)
- Osteoarthritis
- Rheumatic Disease
- Systemic Lupus Erythematosus
- Type II Diabetes
Who it serves
- Big Pharma companies
- Biopharma sponsors
- Biotech companies
- Contract Research Organizations (CROs)
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsGlobal (40+ biopharma and CROs) · United States
Company sourceOfficial website
Company milestones
Platform expansion
Oramed reinitiating previously failed diabetes clinical trial based on PhaseV analysis identifying responsive patient subset. Multiple Phase 2 and Phase 3 trial optimizations across therapeutic areas. ClinOps Innovation Dinner with Insight Partners scheduled May 19 in Boston.
Partnerships
Recorded partners
- Alimentiv
- EMD Serono
- Enlivex
- Insight Partners
- iOMEDICO
- Oramed
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
ML Early-Derived Endpoint Identification
Predict and validate early endpoints to accelerate clinical decision-making
Software · Cloud SaaSCompany source
PhaseV Data Lake
Access 2M+ patient-level data across multiple therapeutic areas
Platform · Cloud SaaSCompany source
Portfolio Optimizer
AI-driven causal modeling to uncover disease drivers and guide treatment strategy
Software · Cloud SaaSCompany source
Response Optimizer
Identify optimal patient subgroups and biomarkers through heterogeneity detection
Software · Cloud SaaSCompany source
Trial Optimizer
AI-powered clinical trial design optimization through millions of simulations
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Robust CATE estimation using novel ensemble methods.Journal of biopharmaceutical statistics · May 28, 2026
Advancing rice and maize disease management: Comparative evaluation of alginate-based azoxystrobin nanoformulation versus conventional fungicide.Pesticide biochemistry and physiology · Jan 1, 2026
Penalized Bayesian methods for product ranking using both positive and negative references.Journal of biopharmaceutical statistics · Oct 1, 2025
A machine learning tool for early identification of celiac disease autoimmunity.Scientific reports · Dec 28, 2024
Colorectal Cancer in Elderly Patients: Insights into Presentations, Prognosis, and Patient Outcomes.Medicina (Kaunas, Lithuania) · Nov 26, 2024
Multi-Epitopic Peptide Vaccine Against Newcastle Disease Virus: Molecular Dynamics Simulation and Experimental Validation.Vaccines · Nov 1, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
40% reduced enrollment
Based on real-world collaborations optimizing trial design and operations
50% lower trial costs
Based on real-world collaborations optimizing trial design and operations
40% shorter trial duration
Based on real-world collaborations optimizing trial design and operations
30%+ higher probability of success
Based on real-world collaborations optimizing trial design and operations
10-40% reduction in sample size
PhaseV adaptive designs without compromising power
10-15% reduced sample size with efficacy
Phase 3 infectious disease study redesign
Alimentiv
Partnership combining GI expertise with PhaseV's ML capabilities for trial simulation, design, and execution
Accelerate success for sponsors and address growing burden of GI diseases more effectively
Big Pharma Company (Kidney Disease)
Portfolio Optimizer used to draw connections between biomarkers and clinical outcomes
Deeper understanding of therapeutic relevance shaped development strategy and informed key decisions for future studies
Big Pharma Company (Metabolic Disease)
Portfolio Optimizer used to uncover and validate new indications for lifecycle management strategy
Guided lifecycle management strategy with data-driven confidence
Big Pharma Company (Oncology)
Site selection for solid tumor oncology program using ClinOps Optimizer
Identified top-performing sites with proven recruitment success while achieving geographic and demographic diversity
Biotech Company (Infectious Disease)
Phase 3 study redesign for infectious disease trial through extensive simulations across various designs
10-15% reduction in sample size while maintaining efficacy
Biotech Company (Rheumatic Disease)
Phase 2 simulations for rheumatic disease, running extensive simulations to guide optimal trial design
Guided client towards optimal design to meet trial objectives
EMD Serono
Identified clinically meaningful subgroups using Response Optimizer for immunology trial
Identified promising subpopulation that otherwise would not have been detected
Enlivex
Identification of higher-responder group for drug Allocetra in knee osteoarthritis patients
Successfully identified higher-responder patient group for osteoarthritis treatment
iOMEDICO
Integration of prospectively collected clinical-grade real world data with PhaseV technology for phase 3 oncology trials
Critical step forward in improving phase 3 oncology trials, helping bring new therapies to market
Lupus Drug Developer
Analyzed Phase 2 RCT for lupus drug to identify early derived endpoint and design adaptive trial
BILAG data at week 8 predicted week 24 improvement, enabling significant reduction in required sample size and overall trial efficiency
Oramed
Reinitiating a previously failed Type II Diabetes clinical trial after identifying a subset of patients who responded well to oral insulin candidate
Identified high-responding patient subgroup validated by external studies including multiple Phase 3 trials
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Oren Hershkovitz
CEO at Enlivex
Stu Bailey
SVP Head of Clinical Measurement Sciences at EMD Serono
Miriam Kidron
CSO at Oramed
Pierre Gaudreault
CEO of Alimentiv
Michael Pröschel
CEO of iOMEDICO
06 · Company updates
Updates from PhaseV
Recent articles published on PhaseV's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.